brand logo
Universal antivenom: Snake collector’s immunity quest opens path

Universal antivenom: Snake collector’s immunity quest opens path

06 May 2025


  • Blood from man bitten 100s of times by deadly species is used to create most broadly protective antivenom yet


He has self-administered more than 850 doses of venom from cobras, mambas, rattlesnakes and other deadly species in pursuit of a singular quest; to develop immunity to snake bites in the hope of helping scientists create a universal antivenom.

Now, the extreme 18-year experiment by a former truck mechanic from Wisconsin, United States (US), Tim Friede, appears to have paid off. Scientists have used antibodies from his blood to create the most broadly protective antivenom to date, which could revolutionise the treatment of snake bites.

“For a period of nearly 18 years, Friede had undertaken hundreds of bites and self-immunisations with escalating doses from 16 species of very lethal snakes that would normally kill a horse,” said the Chief Executive of the US biotech Centivax and the first author of the research, Jacob Glanville. “I thought that if anyone in the world has these properly neutralising antibodies, it’s him.”

The cocktail, which combines two protective antibodies from Friede’s blood and a small molecule venom inhibitor, opens a path towards a universal antivenom, according to research published in the journal Cell. This could transform the ability to treat snake bites, which cause about 140,000 deaths and 300,000 permanent injuries each year.

Most antivenoms rely on a 100-year-old method that involves immunising horses or sheep with venom from single snake species and collecting the antibodies produced. While effective, there is a risk of severe adverse reactions, including anaphylaxis, to the non-human antibodies. And treatments tend to be species- and sometimes region-specific.

“I grew up in Guatemala and they recommend that you try to catch the snake and bring it in a plastic bag so that they can determine if they have an appropriate antivenom,” Glanville said. “It’s not a great option to go chasing after the snake that’s just bitten you.”

Friede, aware of the shortcomings of antivenoms and hoping to fortify himself against accidental bites from his collection of pet snakes, embarked on his self-immunisation quest in 2000. Despite spending four days in a coma in 2001 after being bitten while milking an Egyptian cobra, he continued with his meticulous dose escalation programme, injecting low doses of venom from 16 lethal species before offering up his arms to the snakes to bite.

When Glanville came across an article about Friede, who had documented his project on his YouTube channel, he got in touch. “He was like: ‘Finally. I’ve been waiting for this call for a long time,’” Glanville said.

To design the antivenom, the team selected 19 of the World Health Organisation’s category 1 and 2 deadliest species, including coral snakes, mambas, cobras, taipans and kraits. After isolating candidate antibodies from Friede’s blood, they tested these out in mice envenomated from each species. This allowed them to identify just two antibodies that, when combined with a synthetic antivenom, provided complete protection against 13 of the species and partial protection against the others. “By the time we reached three components, we had a dramatically unparalleled breadth of full protection for 13 of the 19 species and then partial protection for the remaining that we looked at,” Glanville said.

He said that Friede’s meticulous dosing schedule, which involved cyclical exposure to different venoms, meant that any antibodies that offered broader protection were boosted more frequently and were amplified by his immune system.

Snakes fall into four major families, two of which – elapids and vipers – account for the dangerous venomous species. The current research focused on elapids, but Friede also immunised himself against viper bites and the team is developing an equivalent antivenom cocktail for the viper family.

The team is now looking to test the efficacy of the antivenom in the field, initially in dogs brought to veterinary clinics for snake bites in Australia, before moving to human trials.


(The Guardian)




More News..